Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Cost of Human Immunodeficiency Virus (HIV) and Determinants of Healthcare Costs in HIV-Infected Treatment-Naive Patients Initiated on Antiretroviral Therapy in Germany: Experiences of the PROPHET Study.

Tytuł :
Cost of Human Immunodeficiency Virus (HIV) and Determinants of Healthcare Costs in HIV-Infected Treatment-Naive Patients Initiated on Antiretroviral Therapy in Germany: Experiences of the PROPHET Study.
Autorzy :
Valbert F; Institute for Health Care Management and Research, University of Duisburg-Essen, Essen, Germany. Electronic address: .
Wolf E; MUC Research GmbH, Munich, Germany.
Schewe K; German Association of Physicians Specializing in HIV Care Registered Association, Berlin, Germany.
Klauke S; Infektiologikum, Frankfurt, Germany.
Hanhoff N; German Association of Physicians Specializing in HIV Care Registered Association, Berlin, Germany.
Hoffmann C; Infektionsmedizinisches Centrum Hamburg, Hamburg, Germany.
Preis S; Clinovate NET GmbH & Co KG, Munich, Germany.
Pahmeier K; Institute for Health Care Management and Research, University of Duisburg-Essen, Essen, Germany.
Wasem J; Institute for Health Care Management and Research, University of Duisburg-Essen, Essen, Germany.
Neumann A; Institute for Health Care Management and Research, University of Duisburg-Essen, Essen, Germany.
Pokaż więcej
Źródło :
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2020 Oct; Vol. 23 (10), pp. 1324-1331. Date of Electronic Publication: 2020 Aug 14.
Typ publikacji :
Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
Język :
English
Imprint Name(s) :
Publication: Jan./Feb. 2011- : New York : Elsevier
Original Publication: Malden, MA : Blackwell Science, c1998-
MeSH Terms :
Anti-HIV Agents/*economics
HIV Infections/*economics
Health Care Costs/*statistics & numerical data
Adult ; Anti-HIV Agents/therapeutic use ; Drug Costs ; Female ; Germany ; HIV Infections/drug therapy ; Humans ; Male ; Prospective Studies
Substance Nomenclature :
0 (Anti-HIV Agents)
Entry Date(s) :
Date Created: 20201009 Date Completed: 20210219 Latest Revision: 20210219
Update Code :
20210221
DOI :
10.1016/j.jval.2020.04.1836
PMID :
33032776
Czasopismo naukowe
Objectives: The purpose of the prospective clinical and pharmacoeconomic outcomes study of different first-line antiretroviral treatment strategies (PROPHET) was to examine the healthcare costs of human immunodeficiency virus (HIV)-infected persons in Germany treated with different antiretroviral therapy (ART) strategies and to identify variables associated with high costs.
Methods: The setting was a 24-month prospective multicenter observational cohort study in a German HIV-specialized care setting from 2014 to 2017. A microcosting approach was used for the estimation of healthcare costs. Data were obtained via electronic case report forms. The costs were calculated from both the societal and the statutory health insurance perspective. Regression models were performed that took into consideration the impact of several independent variables.
Results: Four hundred thirty-four patients from 24 centers throughout Germany were included. Average annual healthcare costs were €20 118 (standard deviation [SD] €6451) per patient from the societal perspective (n = 336) and €17 306 (SD €4106) from the statutory health insurance perspective (n = 292). Expenditures for the ART medication had the highest impact. Total costs declined in the second year of therapy. There was a significant association between the amount of total cost and clinical or therapeutic variables from both perspectives; a diagnosis of acquired immune deficiency syndrome (AIDS) led to higher costs as well as the chosen ART strategy. Age also increased cost from the statutory health insurance perspective.
Conclusions: The main cost driver of the healthcare costs for HIV-positive patients was antiretroviral drug expenses. Further variables that influenced the costs were identified. The results provide a detailed overview of the resource use of patients in the PROPHET cohort.
(Copyright © 2020 ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies